Breaking News
Top News
-
Caris Life Sciences, Inc. (CAI) Coverage Begins at Neutral as Piper Cites Need for Growth Acceleration
-
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout
-
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma
-
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
-
ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends
-
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
-
BioNTech SE (BNTX) PT Slightly Raised as Morgan Stanley Updates Biopharma Coverage Models
-
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia
-
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead
-
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
-
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds
-
Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends
-
Inspire Medical Systems, Inc. (INSP) PT Reduced to $64 as Truist Updates MedTech Outlook Ahead of Q1
-
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns
-
Evercore ISI Says Sun Pharma Deal Talk for Organon & Co. (OGN) Lacks Confirmation, Remains Speculative
-
Jefferies Adjusts The Cigna Group (CI) Target Lower After Health Insurance Exchange Review
-
Jefferies Updates Elevance Health, Inc. (ELV) Forecasts After Deeper Analysis of Exchange Segment Dynamics
-
Which Is the Better Food and Beverage ETF, Invesco’s PBJ or First Trust’s FTXG?
-
He Never Had To Work And Now His Trust Fund Is Drying Up At 23. Dave Ramsey Says, ‘Go Buy A Leaf Blower. Rich People Are Afraid Of Leaves’
-
5 Insurance Policies You Are (Probably) Overpaying For
2026-02-05





























